Table III.
MLH, E-cadherin, Vimentin, MDM2 and P21 status in relation to clinicopathological variables.
| MLH, n (%) | E-cadherin, n (%) | Vimentin, n (%) | MDM2, n (%) | P21, n (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinicopathological factors | Positive | Negative | P-value | Positive | Negative | P-value | Positive | Negative | P-value | Positive | Negative | P-value | Positive | Negative | P-value |
| Sex | 0.341 | 0.478 | 0.178 | 0.368 | 0.870 | ||||||||||
| Male | 36 (55.4) | 8 (12.3) | 21 (32.3) | 23 (35.4) | 26 (40.0) | 18 (27.7) | 22 (33.8) | 22 (33.8) | 24 (36.9) | 20 (30.8) | |||||
| Female | 15 (23.1) | 6 (9.2) | 12 (18.5) | 9 (13.8) | 16 (24.6) | 5 (7.7) | 13 (20.0) | 8 (12.3) | 11 (16.9) | 10 (15.4) | |||||
| Age/year | 0.045 | 0.714 | 0.987 | 0.019 | 0.180 | ||||||||||
| ≤60 | 30 (46.2) | 4 (6.2) | 18 (27.7) | 16 (24.6) | 22 (33.8) | 12 (18.5) | 23 (35.4) | 11 (16.9) | 21 (32.3) | 13 (20.0) | |||||
| >60 | 21 (32.3) | 10 (15.4) | 15 (23.1) | 16 (24.6) | 20 (30.8) | 11 (16.9) | 12 (18.5) | 19 (29.2) | 14 (21.5) | 17 (26.2) | |||||
| Tumor location | 0.091 | 0.004 | 0.013 | 0.061 | 0.070 | ||||||||||
| EGJ | 25 (38.5) | 4 (6.2) | 9 (13.8) | 20 (30.6) | 14 (21.5) | 15 (23.1) | 14 (22.2) | 19 (29.2) | 12 (18.5) | 17 (26.2) | |||||
| Distal stomach | 26 (40.0) | 10 (15.4) | 24 (36.9) | 12 (18.5) | 28 (43.1) | 8 (12.3) | 21 (32.3) | 11 (16.9) | 23 (35.4) | 13 (20.0) | |||||
| Lauren classification | 0.069 | 0.376 | 0.631 | 0.184 | 0.682 | ||||||||||
| Diffuse | 26 (40.0) | 3 (4.6) | 12 (18.5) | 17 (19.4) | 20 (30.8) | 9 (13.8) | 12 (18.5) | 17 (26.2) | 14 (38.9) | 15 (23.1) | |||||
| Intestinal | 11 (21.5) | 7 (10.8) | 10 (15.4) | 8 (12.3) | 12 (18.5) | 6 (9.2) | 11 (16.9) | 7 (10.8) | 10 (15.4) | 8 (12.3) | |||||
| Mixed | 14 (21.5) | 4 (6.2) | 11 (16.9) | 7 (10.8) | 10 (15.4) | 8 (12.3) | 12 (18.5) | 6 (9.2) | 11 (16.9) | 7 (10.8) | |||||
| Adjuvant therapy | 0.948 | 0.062 | 0.492 | 0.181 | 0.267 | ||||||||||
| XELOX | 26 (40.0) | 7 (10.8) | 13 (20.0) | 20 (30.8) | 20 (30.8) | 13 (20.0) | 22 (33.8) | 11 (16.9) | 20 (30.8) | 13 (20.0) | |||||
| SOX | 25 (38.5) | 7 (10.8) | 20 (30.8) | 12 (18.5) | 22 (33.8) | 10 (15.4) | 26 (40.0) | 6 (9.2) | 15 (23.1) | 17 (26.2) | |||||
MLH, MutL protein homolog 1; MDM2, mouse double minute 2 homolog; P21, cyclin-dependent kinase inhibitor 1A; EGJ, gastro-esophageal junction; XELOX, capecitabine combined with oxaliplatin; SOX, S1 combined with oxaliplatin.